IXICO plc Update regarding Nominated Adviser and Broker (8387X)

TIDMIXI

RNS Number : 8387X

IXICO plc

27 December 2023

IXICO plc

("IXICO" or the "Company")

Update regarding Nominated Adviser and Broker

IXICO plc (AIM: IXI), the medical imaging advanced analytics company delivering insights in neuroscience, announces that, following the completion of the all-share merger between Cavendish Securities plc (previously named Cenkos Securities plc) and Cavendish Financial plc (previously named finnCap Group plc), and as a consequence of internal reorganisation within the Cavendish Group, the Company has changed its Nominated Adviser and Broker from Cavendish Securities plc to Cavendish Capital Markets Limited.

 
 For further information please contact: 
   IXICO plc                                             +44 (0) 20 3763 7499 
   Giulio Cerroni, Chief Executive Officer 
    Grant Nash, Chief Financial Officer 
 
   Cavendish Capital Markets Limited (Nominated 
    Adviser and Sole Broker)                             +44 (0) 20 7220 0500 
   Giles Balleny / Dan Hodkinson (Corporate 
    Finance) 
    Michael F Johnson / Tamar Cranford 
    Smith (Sales) 
 
 
 
  About IXICO 
  IXICO is dedicated to delivering insights in neuroscience 
  to help transform the advancement of investigational therapies 
  for neurological diseases, such as Huntington's disease, Parkinson's 
  disease and Alzheimer's disease. The Company's purpose is 
  to advance medicine and human health by turning data into 
  clinically meaningful information, providing valuable new 
  insights in neuroscience by supporting pharmaceutical companies 
  across all phases of CNS clinical research. IXICO's goal is 
  to be a leading advocate of artificial intelligence in medical 
  image analysis. 
 
  IXICO has developed and deployed breakthrough data analytics, 
  at scale, through its remote access technology platform, to 
  improve the return on investment in drug development and reduce 
  risk and uncertainty in clinical trials for the Company's 
  pharmaceutical clients. 
 
  More information is available on www.IXICO.com and follow 
  us on Twitter @IXICOnews

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

UPDFLFSRFDLFFIV

(END) Dow Jones Newswires

December 27, 2023 02:00 ET (07:00 GMT)

Ixico (LSE:IXI)
Historical Stock Chart
From Jan 2025 to Feb 2025